4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide
|
- $37 - $3400
- Product name: 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide
- CAS: 301692-76-2
- MF: C18H16FNO4S
- MW: 361.39
- EINECS:
- MDL Number:MFCD22570958
- Synonyms:4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide;4-[3-(3-fluorophenyl)-5,5-diMethyl-4-oxo-4,5-dihydrofuran-2-yl]benzene-1-sulfonaMide;5-{4-(aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone;CG-100649;Benzenesulfonamide, 4-[3-(3-fluorophenyl)-4,5-dihydro-5,5-dimethyl-4-oxo-2-furanyl]-;NSAID,inflammatory,Carbonic Anhydrase,Polmacoxib,polyp,colorectal,adenoma,tumor,Inhibitor,COX,Cyclooxygenase,inhibit,Carbonate dehydratase,orthotopic;4-[3-(3-fluorophenyl)-4,5-dihydro-5,5-dimethyl-4-oxo-2-furanyl]-benzenesulfonamide;Calcium acetate Impurity 3
39 prices
Selected condition：
Brand
- aablocks
- ACHEMBLOCK
- AK Scientific
- Arctom
- Biosynth
- Cayman Chemical
- ChemScene
- DC Chemicals
- Sigma-Aldrich
- TRC
Package
- 10mM*1mLinDMSO(Solution)
- 5mg
- 10mM*1mLinDMSO(Solid+Solvent)
- 1mg
- 2mg
- 10mg
- 25mg
- 50mg
- 100mg
- 250mg
- 1g
- Manufactureraablocks
- Product numberAA00C3XP
- Product descriptionPolmacoxib ≥98%
- Packaging5mg
- Price$37
- Updated2026-05-28
- Buy
- Manufactureraablocks
- Product numberAA00C3XP
- Product descriptionPolmacoxib ≥98%
- Packaging10mg
- Price$60
- Updated2026-05-28
- Buy
- Manufactureraablocks
- Product numberAA00C3XP
- Product descriptionPolmacoxib ≥98%
- Packaging25mg
- Price$100
- Updated2026-05-28
- Buy
- Manufactureraablocks
- Product numberAA00C3XP
- Product descriptionPolmacoxib ≥98%
- Packaging50mg
- Price$150
- Updated2026-05-28
- Buy
- Manufactureraablocks
- Product numberAA00C3XP
- Product descriptionPolmacoxib ≥98%
- Packaging100mg
- Price$227
- Updated2026-05-28
- Buy
- ManufacturerACHEMBLOCK
- Product numberY227103
- Product descriptionPolmacoxib 97.00%
- Packaging25MG
- Price$180
- Updated2026-05-27
- Buy
- ManufacturerACHEMBLOCK
- Product numberY227103
- Product descriptionPolmacoxib 97.00%
- Packaging100MG
- Price$425
- Updated2026-05-27
- Buy
- ManufacturerAK Scientific
- Product number3561CR
- Product descriptionPolmacoxib
- Packaging10mg
- Price$266
- Updated2021-12-16
- Buy
- ManufacturerAK Scientific
- Product number3561CR
- Product descriptionPolmacoxib
- Packaging5mg
- Price$185
- Updated2021-12-16
- Buy
- ManufacturerAK Scientific
- Product number3561CR
- Product descriptionPolmacoxib
- Packaging2mg
- Price$117
- Updated2021-12-16
- Buy
- ManufacturerArctom
- Product numberHY-16726
- Product descriptionPolmacoxib 99.70%
- Packaging10mg
- Price$129
- Updated2026-05-26
- Buy
- ManufacturerArctom
- Product numberHY-16726
- Product descriptionPolmacoxib 99.70%
- Packaging25mg
- Price$209
- Updated2026-05-26
- Buy
- ManufacturerArctom
- Product numberHY-16726
- Product descriptionPolmacoxib 99.70%
- Packaging50mg
- Price$314
- Updated2026-05-26
- Buy
- ManufacturerArctom
- Product numberHY-16726
- Product descriptionPolmacoxib 99.70%
- Packaging100mg
- Price$456
- Updated2026-05-26
- Buy
- ManufacturerArctom
- Product numberHY-16726
- Product descriptionPolmacoxib 99.70%
- Packaging10mM*1mLinDMSO(Solution)
- Price$84
- Updated2026-05-26
- Buy
- ManufacturerArctom
- Product numberHY-16726
- Product descriptionPolmacoxib 99.70%
- Packaging10mM*1mLinDMSO(Solid+Solvent)
- Price$80
- Updated2026-05-26
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| aablocks | AA00C3XP | Polmacoxib ≥98% | 5mg | $37 | 2026-05-28 | Buy |
| aablocks | AA00C3XP | Polmacoxib ≥98% | 10mg | $60 | 2026-05-28 | Buy |
| aablocks | AA00C3XP | Polmacoxib ≥98% | 25mg | $100 | 2026-05-28 | Buy |
| aablocks | AA00C3XP | Polmacoxib ≥98% | 50mg | $150 | 2026-05-28 | Buy |
| aablocks | AA00C3XP | Polmacoxib ≥98% | 100mg | $227 | 2026-05-28 | Buy |
| ACHEMBLOCK | Y227103 | Polmacoxib 97.00% | 25MG | $180 | 2026-05-27 | Buy |
| ACHEMBLOCK | Y227103 | Polmacoxib 97.00% | 100MG | $425 | 2026-05-27 | Buy |
| AK Scientific | 3561CR | Polmacoxib | 10mg | $266 | 2021-12-16 | Buy |
| AK Scientific | 3561CR | Polmacoxib | 5mg | $185 | 2021-12-16 | Buy |
| AK Scientific | 3561CR | Polmacoxib | 2mg | $117 | 2021-12-16 | Buy |
| Arctom | HY-16726 | Polmacoxib 99.70% | 10mg | $129 | 2026-05-26 | Buy |
| Arctom | HY-16726 | Polmacoxib 99.70% | 25mg | $209 | 2026-05-26 | Buy |
| Arctom | HY-16726 | Polmacoxib 99.70% | 50mg | $314 | 2026-05-26 | Buy |
| Arctom | HY-16726 | Polmacoxib 99.70% | 100mg | $456 | 2026-05-26 | Buy |
| Arctom | HY-16726 | Polmacoxib 99.70% | 10mM*1mLinDMSO(Solution) | $84 | 2026-05-26 | Buy |
| Arctom | HY-16726 | Polmacoxib 99.70% | 10mM*1mLinDMSO(Solid+Solvent) | $80 | 2026-05-26 | Buy |
Properties
Melting point :155-156 °C
Boiling point :527.7±60.0 °C(Predicted)
Density :1.361±0.06 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :DMF: 20 mg/ml; DMSO: 20 mg/ml; DMSO:PBS (pH 7.2)(1:8): 0.5 mg/ml; Ethanol: 5 mg/ml
form :A crystalline solid
pka :10.21±0.10(Predicted)
color :Light yellow to green yellow
InChI :InChI=1S/C18H16FNO4S/c1-18(2)17(21)15(12-4-3-5-13(19)10-12)16(24-18)11-6-8-14(9-7-11)25(20,22)23/h3-10H,1-2H3,(H2,20,22,23)
InChIKey :IJWPAFMIFNSIGD-UHFFFAOYSA-N
SMILES :C1(S(N)(=O)=O)=CC=C(C2=C(C3=CC=CC(F)=C3)C(=O)C(C)(C)O2)C=C1
Boiling point :527.7±60.0 °C(Predicted)
Density :1.361±0.06 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :DMF: 20 mg/ml; DMSO: 20 mg/ml; DMSO:PBS (pH 7.2)(1:8): 0.5 mg/ml; Ethanol: 5 mg/ml
form :A crystalline solid
pka :10.21±0.10(Predicted)
color :Light yellow to green yellow
InChI :InChI=1S/C18H16FNO4S/c1-18(2)17(21)15(12-4-3-5-13(19)10-12)16(24-18)11-6-8-14(9-7-11)25(20,22)23/h3-10H,1-2H3,(H2,20,22,23)
InChIKey :IJWPAFMIFNSIGD-UHFFFAOYSA-N
SMILES :C1(S(N)(=O)=O)=CC=C(C2=C(C3=CC=CC(F)=C3)C(=O)C(C)(C)O2)C=C1
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|
Description
Polmacoxib, also known as (CG-100649), is a first-in-class NSAID which is a dual inhibitor of COX-2 and carbonic anhydrase (CA). The drug, which was approved in South Korea for the treatment of colorectal cancer (CRC) in 2015 and whose discovery has been described by workers at AmorePacific R&D, interacts with CA in red blood cells, providing a novel “tissue-specific” transport mechanism that is designed to deliver sustained levels of drug to inflamed tissues while maintaining low systemic exposure. Although the unique dual COX-2/CA inhibition is designed to provide potentially superior safety to cardiovascular, renal, and gastrointestinal tissues compared to traditional NSAIDs or COX-2 inhibitor drugs, the long-term safety profile of the drug, particularly cardiovascular risks notoriously associated with inhibition of COX-2, has yet to be determined, and the drug is currently not approved for use in any other country outside of South Korea.Related product price
Suppliers and manufacturers
career henan chemical co
Shenzhen Shengda Pharma Limited
BOC Sciences
Hefei Hirisun Pharmatech Co., Ltd
Zhejiang J&C Biological Technology Co.,Limited
Wuhan Topule Biopharmaceutical Co., Ltd
Shanghai Scochem Technology Co., Ltd
Zibo Hangyu Biotechnology Development Co., Ltd
$1.00
4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide CAS:301692-76-2
4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide CAS:301692-76-2
